min/1.73 m 2 or anuric. Vascular access was a fistula (13/15) or a central venous catheter (2/15) . Dialysis was delivered daily, six days a week in 3 hourly sessions (18 h/week), in a predilution OL-HDF mode, allowing a high convective volume (18 to 27 L/m 2 body surface area per session), Kt/ V urea on line measured at least 1.4 per session. Results. Mean growth velocity increased from 3.8 ± 1.1 cm/year at inclusion to 14.3 ± 3.8 cm/year during the first year of D-OL-HDF, resulting in a change in height standard deviation score (SDS) over the follow-up period from −1.5 ± 0.3 SDS to +0.2 ± 1.1 SDS. Increase in body mass was also noted without impaired control of blood pressure. Time-average deviation for urea (TAD urea ) was low at 2.5 ± 0.4 as was TAD bicarbonate due to the normal pre and post dialysis bicarbonate levels, respectively, 23.6 ± 0.5 mmol/ L and 26.6 ± 0.5 mmol/L. The absence of any dietary restrictions permitted a mean protein diet intake (PDI) of 2.5 ± 0.2 g/kg/day (PDI measured from a 3-day diet survey), contrasting with a mean normalized protein nitrogen appearance (nPNA) of 1.53 ± 0.12 g/kg/day (nPNA calculated from urea dialytic kinetic). A low C-reactive protein was noted in 13/15 children, and mean β 2 microglobulin
Introduction
Over the last few decades, the growth outcome for children with end stage renal failure has improved remarkably [1] [2] [3] . Nevertheless, even optimal care including daily administration of recombinant human growth hormone (rhGH) has proven inadequate in improving growth [4, 5] . Indeed, several studies [1] [2] [3] [4] [5] have demonstrated that 35-50% of children with renal insufficiency have an adult height below −2 standard deviation scores (SDS) of the normal population and below their familial target height. This problem remains a major obstacle not only in their medical management but also as a part of their everyday lives [1, 3] . Poor growth of children with end stage renal disease has been associated with an increased risk of hospital admissions and death [6, 7] , possibly related to their poor nutritional status, including both malnutrition and cachexia [3, 8, 9] . In children on chronic dialysis, malnutrition related to poor appetite and restrictive diet can be managed by dietary support [2, 7] . However, this may not always solve the problem due to the cachexia and muscle wasting which occur in uraemic patients [8] . It is known that several uraemic factors can activate the ubiquitin proteasome system to degrade protein stores [8] , such as metabolic acidosis, inflammation and uraemic toxin retention, which occur in haemodialyzed patients [10] . In children on chronic dialysis, growth may be used as a parameter to measure the optimal balance between nutrition, i.e. malnutrition and/or cachexia and adequate dialysis [9, 11] . The three times a week programme (three times, 4 h) usually used in children on long-term dialysis does not allow for normal growth, therefore the case for an increased frequency was proposed [12, 13] . However, intensive and daily dialysis is time consuming and so is not ideal in the paediatric population [14] . Knowing on the one hand the advantages of daily haemodialysis [15] [16] [17] [18] and on the other hand the on line haemodiafiltration effects on uraemic toxin purification [19] [20] [21] , we used incentre daily on line haemodiafiltration (D-OL-HDF) in children [11, 22, 23] , that was both daily dialysis and convective flow added to haemodialysis.
For this study, we prospectively collected data for growth in children on in-centre D-OL-HDF and assessed nutritional status and growth outcome with the hope of confirming our previous published data [11] .
Materials and methods
This was a single centre, observational, prospective and non-randomized study. We included 15 children (Table 1 ) from September 2004 to April 2008, five of which had been included in previous publications [11] . Analysis of the data was performed in March 2009. The inclusion criteria were residual renal function <3 mL/min/1.73 m 2 defined as the mean of K urea and K creat or anuria, prepubertal development stage (or early pubertal stage in three cases; Table 1 ), >6 months follow-up on D-OL-HDF and parents and child agreeing to in-centre daily dialysis. School lessons were provided by qualified teachers after discussion with the child's own school for 2-h periods during each dialysis session. All had a journey time to the hospital of <1 h. The end point of D-OL-HDF follow-up was kidney transplantation, which was performed by the time of final analysis in 12/15 children, whilst 3/15 were still awaiting transplantation. During this study period, six children on D-OL-HDF were excluded from the analysis, as they underwent kidney transplantation before 6 months follow-up was complete. Only one child and his parents didn't accept the daily schedule due to personal inconvenience despite the short travel time (<30 min) to hospital. The good acceptance rate of our daily in-centre dialysis programme was due to the child and care givers' positive perceptions of the results seen over time. All children were on rhGH treatment with 1 IU/ kg/week, by daily subcutaneous injections, started at least 12 months before the D-OL-HDF. At inclusion, their mean age was 8 years and 3 months (range, 3 years and 6 months to 14 years and 6 months). Before inclusion in the study, three children were on standard OL-HDF (4 h sessions three times a week), four were on chronic peritoneal dialysis (changed due to difficulties with diet, medications and dry weight achievement) and the remaining eight of them had started dialysis with D-OL-HDF. Vascular access was via a fistula (n = 13) or a central venous jugular catheter (n = 2). The dialysis schedule consisted of 3 hourly sessions six times a week (18 h/week), using highly permeable dialysers (FX 40 or FX 60, polysulfone, Fresenius), OL-HDF in a predilution mode, allowing a per session convective volume of 18 to 27 L/m 2 body surface area (BSA), blood flow of 150 mL/min/m 2 BSA adjusted to achieve a Kt/ V urea of at least 1.4 per session, on line measured (OCM, Fresenius, 4008 E machine) and dialysate flow of 500 mL/min. Dialysate and reinfusion fluid was bicarbonate buffered, 32 mmol/L with dextrose 1 gr/L. Pre dialysis blood pressure was measured immediately before the dialysis session with an automated blood pressure monitor and was expressed as the systolic, diastolic and mean blood pressure. Tolerance during the dialysis session (i.e. hypotensive episodes and cramps) was recorded regularly. Post dialysis recovery time was recorded in minutes [24] (the time taken before the child was able to stand and walk after the end of the dialysis session). Diet was without restrictions and normal for age, the only limitation being the potassium intake especially in the day 'off dialysis'due to its potential cardiovascular toxicity. In 2/15 cases, a potassium chelator was prescribed for the day 'off dialysis' due to their 'free' but not always normal dietary intake; these two children were of Romany traveller origin living in a trailer/caravan site and were also prescribed CaC03 as a daily phosphate binder. Dietary protein intake (DPI) was calculated from a nutritional survey carried out for 3 days each month. Side effects, like hospitalisation or vascular access problems (infection, thrombosis and stenosis), were noted. Growth in height (centimetres), height SDS and body mass index (BMI; kg/m 2 BSA) were assessed monthly. Height SDS achieved was compared to the familial target height, calculated as the mid-parental target height ± 13 cm depending on their gender [father height + mother height ± 13 (cm) / 2]. Growth velocity was expressed in centimetres per year, measured (or calculated in patient 12, from 11 months follow-up), and then for each individual compared to the year before starting D-OL-HDF, the first year on treatment and the mean achieved during D-OL-HDF. The following urea kinetic parameters were calculated: urea time-average deviation (TAD urea ) [25] , Kt/V urea according to the Daugirdas single-pool second-generation formula and normalized protein nitrogen appearance (nPNA) [10, 26] . Urea kinetic parameters and standard pre dialysis blood analysis [i.e. haemoglobin, potassium, phosphates, bicarbonate and pH using a blood gas analyzer at a standardized temperature of 25°C, C-reactive protein (CRP), β 2 microglobulin and intact parathyroid hormone (iPTH)] were performed on samples collected at a mid-weekly dialysis sessions; CRP was measured monthly and β 2 microglobulin and iPTH on a 3 months basis. TAD bicarbonate was calculated using the same formula applied for urea [25] , derived from pre and post dialysis values. Post dialysis samples were performed from 3 to 5 min after stopping dialysis flow, with a blood flow of 50 mL/min [19] .
The results are expressed as arithmetic means ± SD with range if needed, in brackets. Z score was calculated for blood pressure results. The Student's t-test was used for comparison. Pearson correlation coefficient (r) was applied. A probability of P < 0.05 was considered significant.
Results
The mean time on D-OL-HDF was 20.5 ± 8 months (11-39 months) . No side effects were noted, in particular, no vascular access problems. Tolerance was good, with no significant post dialysis recovery time. The mean growth velocity (Table 2 ) was statistically lower the year before starting D-OL-HDF, 3.8 ± 1.1 cm/year (2.0-5.2 cm/year) than in comparison to the first year of treatment, 14.3 ± 3.8 cm/year (8.5-20.5 cm/year) and also when compared to the mean over the whole follow-up period, 8.9 ± 2.2 cm/year (4.7-14.7 cm/year). During the first year of D-OL-HDF, the growth velocity was statistically higher compared to the mean over the whole daily follow-up period. This growth velocity leads to a significant change in height SDS (Table 2) , from the start of D-OL-HDF −1.5 ± 0.3 SDS (−3.5-0.0) to the end of daily +0.2 ± 1.1 SDS (−1.1 to +1.9), which resulted in the children achieving a mean height of just over the mid-parental target height by +0.3 ± 0.7 SDS (−1.3 to +1.6). The mean BMI increased ( Table 2) antihypertensive drug (patients 4 and 5). Mean pre dialysis haemoglobin (g/dL) showed no significant tendency to increase between the start of D-OL-HDF, 11.4 ± 1.2 and end of the study, 12.5 ± 0.9. The iPTH (pg/mL) didn't change significantly, respectively, 143 ± 47 and 195 ± 89. Mean pre dialysis parameters are given in Table 3 . Mean pre dialysis phosphate levels were in the normal range, 1.39 ± 0.05 mmol/L, despite a high protein intake, mean DPI of 2.5 ± 0.2 g/kg/day. A high mean CRP was noted in patients 4 and 5 having chronic bronchitis (respectively, 47 and 32 mg/L), related to their familial ciliary disease ( Table 1 ). All other children had a mean CRP <4 mg/L. Mean post dialysis bicarbonate level was 26.6 ± 0.5 mmol/L, only marginally elevated in comparison with the pre dialysis value, resulting in a low mean TAD bicarbonate . Mean TAD urea was low, 2.5 ± 0.4. DPI was significantly higher than nPNA. No significant correlation was noted between growth velocities and TAD bicarbonate , nor DPI or nPNA. Only a weak correlation was noted between DPI and nPNA, r = 0.62. Two individual growth charts (Figure 1) show examples of the growth pattern changes: height (TC being the mid-parental target height), weight, growth velocity and BMI.
Discussion
Our observational, prospective but non-randomized study on in-centre D-OL-HDF which comprises both daily dialysis and on line haemodiafiltration (convective flow) clearly shows an unusual growth velocity in children despite being on chronic dialysis resulting in a pattern of catchup growth. Despite the optimization of care over previous decades, catch-up growth is very uncommon in children on chronic haemodialysis. Subsequent evaluations following 6 and 12 months of dialysis demonstrated little to no improvement in height SDS during the period of dialysis [3] . Moreover, there is all too often a loss in height SDS which can be correlated to the duration of chronic haemodialysis, with a mean of −0.4 to −0.8 height SDS lost per year [6] . This growth retardation occurring over the dialysis treatment period should be limited as much as possible, as it is known that the final adult height achieved is related to the height deficit recorded at the time of kidney transplantation [27] . There is evidence to suggest that growth of children on dialysis is better during the first 2 years of life, especially noted in those receiving peritoneal dialysis [2] . This, however, is not the age range of our study population, mean age 8 years and 3 months at the start of D-OL-HDF. It is also often documented that the increase in growth velocity seen secondary to a change in therapy is related to the severity of the growth retardation [2] [3] [4] [5] [6] . Interestingly, our population started D-OL-HDF with a mean growth retardation of −1.5 ± 0.3 height SDS, they were on rhGH for >1 year and were receiving conventional optimal care [2, 7, 19] . Some children were already on OL-HDF, but only on a three times a week. The catch-up growth velocity noted in the first year of daily dialysis declined over time ( Table 2 ) with a significant lower mean growth rate thereafter. Nevertheless, the mean height SDS at the end of daily dialysis was + 0.2 ± 1.1 height SDS and in the range of the familial target height. Hence, despite the relative normalization of growth rate after the first year of daily dialysis, the familial target height is still being achieved-this may explain why the catch-up growth velocity declines over time. However, we do have to remark that this achieved height SDS gain is not sufficient to guarantee a normal adult height but should rather be viewed as an excellent predictive factor for final adult height. This catchup growth was not associated with significant changes in mean iPTH. However, over the study period, we did record transiently higher iPTH values in patients 4 and 5. The noted catch-up growth was associated with a significant gain in BMI over the duration of daily dialysis. Such a BMI increase was also noted in our 'pilot trial' [22] and was paradoxically associated with better blood pressure control, therefore presumed in part to be secondary to an improved anabolic state as a result of less malnutrition and less cachexia (review in [8, 10] ) and less growth hormone resistance [28, 29] . Throughout the study, we ensured optimal blood pressure control during D-OL-HDF. All children had a normal blood pressure recorded at the start of every session despite 2/15 being on the antihypertensive medication enalapril. The impact of D-OL-HDF on catch-up growth, i.e. less resistance to rhGH in children on chronic dialysis, appears to be multi factorial, possibly due to the following factors: dialysis modality, i.e. OL-HDF (high convective dialysis flow and use of ultrapure dialysate), dialysis frequency and dialysis time, i.e. daily dialysis six times a week for 3 h and lastly, the absence of malnutrition, i.e. due to free diet and good appetite. With the use of ultrapure dialysate, OL-HDF appears to be an optimal haemodialysis procedure at least in terms of both uraemic toxin removal and of reduced dialysis induced inflammation [21] , two factors which potentially limit uraemic protein wasting [8, 10] and so may promote growth for children despite being on chronic dialysis [9] . Haemodiafiltration applied daily improves renal blood purification [30] [31] [32] .
In our D-OL-HDF study, not only is TAD urea low but it is also a marker of middle molecule weight uraemic toxins, for example β 2 microglobulin, which is under the suggested 25 mg/L 'optimal' pre dialysis threshold level [20] . It could be speculated that the achievement of low β 2 microglobulin levels in our study, i.e. 15.3 ± 3.3 mg/L should be a surrogate marker for the elimination of other All parameters were assessed weekly except for β 2 microglobulin determined each third month. middle molecular uraemic toxins as well [20, 21] . Despite the daily OL-HDF which involves not only a process of diffusion but also a significant convective mass transfer, i.e. 18-27 L/m 2 BSA per session, we didn't observe any signs of malnutrition despite a potential for albumin loss in the dialysate [33] as may be associated with intensive convective dialysis regimes. Moreover, it could be speculated that this presumed enhanced albumin loss in the dialysate [33] observed during D-OL-HDF could actually be a positive side effect due to the increased excretion of toxic uraemic molecules which are albumin bound such as indoxyl sulphate [20] . Also of importance is the low CRP noted, a marker of inflammation. In almost all our cases, CRP was <4 mg/L. Interestingly, in cases 4 and 5, the elevated CRP related at least in part to their chronic lung disease and did not impair the growth velocity induced by D-OL-HDF. Pre dialysis bicarbonate levels were within the normal range. Interestingly, we noted a very low mean TAD bicarbonate , thus a limited acidosis-alkalosis wave both during the dialysis sessions and between the dialysis sessions. This profile presumed to be a better correction of the dialysis acidosis/alkalosis waves usually noted for a three times a week dialysis schedule [15, 28] , should potentially impact on patient nutrition (review in [10] ) possibly via the ubiquitin proteasome system reducing protein wasting, i.e. cachexia (review in [8] ). In fact, we noted in our study a significant discrepancy between the measured DPI and the calculated nPNA. The nPNA formula used [26] was applied the same day of the week for all patients, mid-week as recommended [10] . It is known that nPNA does not reflect daily protein intake alone but also protein turnover [10] . Better correction of metabolic acidosis in dialysed patients as achieved in our study by applying D-OL-HDF should reduce protein catabolism and muscle wasting, presumably resulting in less growth hormone resistance [8, 10, 28] . Nevertheless, we have to remark that from our study we cannot propose a change in the recommended optimal pre dialysis serum bicarbonate level, i.e. 20-22 mmol/L [10] . The reported increase in growth velocity with BMI gain over D-OL-HDF Xis also likely to be attributable in part to less malnutrition, i.e. optimized food intake. Despite the absence of dietary restrictions, control of both phosphate and potassium serum levels was easily achieved, with only a limited need to prescribe chelators, in particular only potassium chelators the day 'off dialysis'. This optimal control is likely to be not only related to purification parameters, i.e. removal capacities of D-OL-HDF, but presumably [8, 10, 29] are also in part secondary to the induced anabolic state. It could be speculated that optimized phosphate levels should positively impact on the cardiovascular morbidity/mortality outcome [34, 35] .
The reported catch-up growth achieved in children receiving chronic dialysis on the in-centre D-OL-HDF programme should be recognized as being a result of several potential factors which contribute towards patient care and management [36] : on the one hand, free diet and good appetite result in less malnutrition, and on the other hand, daily convective dialysis modality purification, reduced inflammation and no metabolic acidosis lead to less uraemic protein wasting. The impact of increased daily activity due to less fatigue in children on daily dialysis presumably may also be presumed to play a role in explaining this growth pattern and body mass increase [37, 38] . At present, it is not well known if all the different available daily dialysis modalities are equivalent in terms of catch-up growth [14, 39] . Some may have specific benefits but also relative disadvantages such as the major cost increase of daily incentre versus conventional in-centre dialysis or daily at home dialysis and the impact on social integration and activities of daily living of daily in-centre versus nocturnal dialysis sessions [14, 40] . Nevertheless, daily haemodialysis regimens should not just be thought of as a rescue modality [16] but should also be considered in children facing long waiting times on chronic dialysis [14] . Ongoing paediatric daily dialysis registry [41] should help in clarifying the optimal 'daily haemodialysis' regime, daily nocturnal, daily at home or in-centre OL-HDF delivered daily [14, 39] taking into account the potential benefits, the important cost increase and the economical resources available.
